Cambridge, Massachusetts-based CAMP4 Therapeutics Corp. will make its trading debut on the Nasdaq Global Market, under the ticker symbol, "CAMP" today, Oct. 11, 2024.
This clinical-stage biotechnology company developing RNA-targeting therapeutics for the treatment of metabolic disorders, central nervous system, or CNS conditions and SYNGAP-related disorders.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com